Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Trinidad & Tobago Wellness Today.
Press releases published on July 4, 2025
L’eau, la boisson vedette de plus de 42 000 jeunes avec le Défi Tchin-tchin dans mon camp!
GlobeNewswire
·
July 4, 2025
MONTRÉAL, 04 juill. 2025 (GLOBE NEWSWIRE) -- Cette semaine, du 30 juin au 4 juillet, plus de 42 000 jeunes campeur·euse·s à travers le Québec ont levé leur verre d’eau bien haut pour célébrer l’importance d’une saine hydratation! En relevant le Défi Tchin- …
Sodium Perborate Market worth $184.0 million in 2030, at 3.7%, says MarketsandMarkets™
GlobeNewswire
·
July 4, 2025
Delray Beach, FL, July 04, 2025 (GLOBE NEWSWIRE) -- In terms of value, the Sodium Perborate Market is expected to reach USD 184.0 million in 2030 from USD 153.3 million in 2025, registering a CAGR of 3.7%, as per the recent study by MarketsandMarkets™. …
Nxera Pharma to Receive US$4.8 Million in Milestone Payments Following Centessa’s Initiation of Clinical Development of ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist
GlobeNewswire
·
July 4, 2025
Tokyo, Japan and Cambridge, UK, 4 July 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that it will receive US$4.8 million in milestone payments from Centessa Pharmaceuticals pursuant to its research collaboration with …
AB Science : Le masitinib reçoit l'autorisation de la FDA et de l'EMA pour l’etude confirmatoire de phase 3 dans le cancer de la prostate métastatique hormono-resistant
GlobeNewswire
·
July 4, 2025
COMMUNIQUÉ DE PRESSE LE MASITINIB REÇOIT L'AUTORISATION DE LA FDA ET DE L'EMA POUR L’ETUDE CONFIRMATOIRE DE PHASE 3 DANS LE CANCER DE LA PROSTATE MÉTASTATIQUE HORMONO-RESISTANT, AVEC UNE SÉLECTION DES PATIENTS BASÉE SUR DES BIOMARQUEURS CIBLANT LA …
AB Science: Masitinib receives FDA and EMA authorization for confirmatory phase 3 trial in metastatic castrate-resistant prostate cancer
GlobeNewswire
·
July 4, 2025
PRESS RELEASE MASITINIB RECEIVES FDA AND EMA AUTHORIZATION FOR CONFIRMATORY PHASE 3 TRIAL IN METASTATIC CASTRATE-RESISTANT PROSTATE CANCER, WITH BIOMARKER-DRIVEN PATIENT SELECTION TARGETING POPULATION MOST LIKELY TO BENEFIT Paris, July 4, 2025, 8am CET AB …
Strüngmann Award zeichnet Gründerteam von Araris Biotech als Preisträger 2025 aus
GlobeNewswire
·
July 4, 2025
Die Expertenjury wählte Dr. Dragan Grabulovski, Dr. Philipp Spycher und Dr. Isabella Attinger-Toller von Araris Biotech, aus einer Gruppe herausragender Life-Science-Unternehmer aus Das Gründerteam von Araris Biotech entwickelt eine bahnbrechende …
Strüngmann Award Honors Araris Biotech Founding Team as 2025 Winner
GlobeNewswire
·
July 4, 2025
The expert jury selected Dragan Grabulovski, Ph.D., Philipp Spycher, Ph.D., and Isabella Attinger-Toller, Ph.D. of Araris Biotech, from a group of outstanding life science entrepreneurs The founding team is developing a breakthrough technology to establish …